ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0034

Association of Anti-Tropomyosin Alpha-4 Autoantibodies with Cutaneous Manifestations in Juvenile Dermatomyositis
Abstract Number: 0035

Anti-Peroxiredoxin 6 and Anti- Myosin Light Polypeptide 6 Autoantibodies with Interstitial Lung Disease and Severe Disease in Juvenile Dermatomyositis
Abstract Number: 0036

Patient-specific and Disease-related Determinants for Cardiovascular Disease (CVD) Risk Stratification in the APPLE (Atherosclerosis Prevention in Paediatric Lupus Erythematosus) Clinical Trial Cohort
Abstract Number: 0037

Dual (and Dueling) Fibroblast Differentiation Is Integral to the Pathogenesis of Anti-Ro Mediated Congenital Heart Block and Provides a Novel Biomarker of Severity
Abstract Number: 0038

STING Antagonist (IFM4490) Inhibits STING Activation and STING Dependent Signal Transduction in Patients with STING-associated Vasculopathy with Onset in Infancy (SAVI)
Abstract Number: 0039

Type I and Type II Interferon and NF-κB-Response Gene Scores and Serum Cytokine Levels in Patients with Various Systemic Autoinflammatory Diseases
Abstract Number: 0040

Plasma Proteomic Signatures in Juvenile Dermatomyositis Highlight Novel Proteins and a Protein Module That Associate with Skin and Global Disease Activity
Abstract Number: 0041

Modeling Juvenile Dermatomyositis with Engineered Human Skeletal Muscle: Effects of Type I Interferonβ and Janus Kinase Inhibitors
Abstract Number: 0042

The Pathogenic Role of Lymphatic Vessels in Autoimmune Valvular Carditis
Abstract Number: 0043

Non-invasive Tape Strip Gene Expression Profiling of Lesional Juvenile Dermatomyositis Skin Identifies Immunoregulatory Module That Associates with Skin, Muscle and Global Disease Activity
Abstract Number: 0044

Follistatin-like Protein 1 Alters T Cell Receptor Signaling Dynamics in Vitro, While Expression in Vivo Correlates with Disease and Deficiency Increases Acute Inflammation in a Mouse Model of Kawasaki Disease
Abstract Number: 0045

Rheumatoid Arthritis Patient-derived Anti-citrullinated Protein Antibodies (ACPAs) Ameliorate Joint Inflammation in Early Collagen-antibody Induced Arthritis (CAIA)
Abstract Number: 0046

Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion
Abstract Number: 0047

Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
Abstract Number: 0048

Combination of Repetitive Inhalant Endotoxin Exposure and Collagen-induced Arthritis Interact in a Testosterone-dependent Manner to Drive Inflammatory Lung Disease Processes and Arthritis Severity in Mice

« Previous Page
1
…
4
5
6
7
8
…
154
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].